LongevityPreclinical

TA-1

Thymosin Alpha-1 Fragment

AI explanation

TA-1

TA-1 is a shortened version of a naturally occurring peptide called Thymosin Alpha-1, which your immune system naturally produces. Researchers are interested in TA-1 because they've found that you don't actually need the whole 28-piece protein to get the benefits—just a smaller fragment works almost as well. This matters because a smaller peptide is cheaper to make and might move through your body more effectively.

Here's how it actually works: Think of your immune system like a security team that needs good communication. TA-1 acts like a messenger that wakes up your dendritic cells and T-cells—the coordinators and soldiers of your immune response. When TA-1 activates these cells, they get better at recognizing invaders and displaying them like wanted posters to the rest of your immune team. This triggers your body to produce more interferon-gamma and interleukin-2, which are essentially alarm chemicals that ramp up your natural killer cells and restore T-cell function when your immune system has been weakened. The whole point of studying these smaller fragments is finding the absolute minimum you need to trigger this immune-boosting effect while making the peptide easier and cheaper to produce.

Dosage Information

Typical Dose

1.6 mg (equivalent to Thymosin Alpha-1 dosing)

Frequency

Twice weekly

Anytime

Administration

Subcutaneous injection

Half-Life

2 hours

Notes

Limited differentiation from full Thymosin Alpha-1 in practice. See Thymosin Alpha-1 entry for the primary clinical evidence base.

Why this matters

Same as Thymosin Alpha-1; subcutaneous injection with effects outlasting plasma levels.

Protocol cycle

ongoing· Twice weekly dosing, no cycling protocol specified

Dose Calculator

Calculate your draw amount for an insulin syringe (U-100)

Concentration: 2,500 mcg/mL

Sign in to save your reconstitution settings for this peptide

Draw to the

64

unit mark

020406080100

Draw 64 units for your 1600mcg dose of TA-1

This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.

Where does TA-1 sit?

See how this peptide compares across all 150 peptides in our database.

Evidence Score

0.22

Clinical trials
0.0035%
Literature
0.4330%
Community
0.0020%
Completeness
0.6315%
1 reviews

Potential Side Effects

Injection site reactions (common)Mild flu-like symptoms initially (uncommon)Headache (rare)
Pep Talk

TA-1 discussions

Quick Facts

Administration
Subcutaneous injection
Typical Dose
1.6 mg (equivalent to Thymosin Alpha-1 dosing)
Frequency
Twice weekly
References
0 curated + 50 from PubMed
Evidence Score
0.2 / 100

Frequently Asked Questions about TA-1

What is TA-1?

TA-1 refers to short active fragments of Thymosin Alpha-1 that retain immunomodulatory activity with potentially improved pharmacokinetics. While full Thymosin Alpha-1 (documented separately as Thymosin Alpha-1 in this database) has extensive clinical evidence TA-1 fragments represent an area of active investigation for more targeted immune modulation. This entry covers research into the minimal active sequence required for Thymosin Alpha-1's immunological effects and the development of next-generation immune modulators derived from this peptide.

How does TA-1 work?

TA-1 fragments act on dendritic cells and T-lymphocytes through similar mechanisms to full Thymosin Alpha-1 — enhancing MHC class II expression improving antigen presentation and stimulating Th1 cytokine production particularly interferon-gamma and interleukin-2. The minimal active fragment retains the ability to enhance natural killer cell activity and restore T-cell function in immunocompromised states. Research into TA-1 fragments aims to identify the smallest sequence that retains full biological activity allowing for more economical synthesis and potentially improved tissue penetration compared to the full 28-amino-acid parent peptide.

What is the recommended dosage for TA-1?

The typical dose is 1.6 mg (equivalent to Thymosin Alpha-1 dosing). Twice weekly. Administration: Subcutaneous injection. Limited differentiation from full Thymosin Alpha-1 in practice. See Thymosin Alpha-1 entry for the primary clinical evidence base.

What are the side effects of TA-1?

Injection site reactions (common). Mild flu-like symptoms initially (uncommon). Headache (rare)

What is the TA-1 cycle protocol?

TA-1 is typically cycled ongoing. Twice weekly dosing, no cycling protocol specified

Questions reflect common community inquiries. This is not medical advice.